Nature Reviews Cancer content April 2013 Volume 13 Number 4 pp 219-290

Advertisement
Roche's X-tremeGENE Transfection Reagents Transfect efficiently with low cytotoxicity proven in 275 different cell types...over 130 cancer cells. Free sample and protocols at http://www.x-tremegene.roche.com For life science research only. Not for use in diagnostic procedures.
TABLE OF CONTENTS
April 2013 Volume 13 Number 4
Impact Factor 37.545 *	In this issue Research Highlights Progress Reviews Perspectives Also this month  Featured article: Mechanistic links between COPD and lung cancer A. McGarry Houghton
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BEATSON INTERNATIONAL CANCER CONFERENCE Targeting the Tumour Stroma 7 - 10 July 2013 Glasgow University This meeting will highlight recent exciting research into the role played by the tumour stroma in cancer progression and how stromal tissue may be targeted to treat the disease. Deadline for registration, payment and abstract submission - 6 May 2013
Advertisement
Get the most from your NGS data with Sequenom’s MassARRAY® system Validate from tens to thousands of samples across tens to hundreds of SNPs Design you own assays against any SNP of interest Run a variety of applications including genotyping, DNA methylation and somatic mutation analysis
RESEARCH HIGHLIGHTS Top Tumour evolution: Weighed down by passengers? p219 | doi:10.1038/nrc3488 A new study combines evolutionary simulations with clinical mutation data to suggest that passenger mutations in cancers might have more functional consequences than is often assumed. PDF Leukaemia: Knowing left from right p220 | doi:10.1038/nrc3487 A paper published in Science delves further into the mechanisms through which mutations in isocitrate dehydrogenase contribute to leukaemogenesis. PDF Genomic instability: DNA transitions p220 | doi:10.1038/nrc3490 Burns, Lackey and colleagues find that the cytosine deaminase APOBEC3B seems to be important for the mutation rate in breast cancer. PDF Melanoma: Horses for courses p222 | doi:10.1038/nrc3491 A subset of melanoma cells express high levels of PGC1α, which alters their metabolic phenotype compared with melanoma cells that do not express PGC1α. PDF Microenvironment: Making connections p222 | doi:10.1038/nrc3492 Tumorigenic genetic and epigenetic changes in epithelial cells occur as a result of increased inflammation following the loss of transforming growth factor-β receptor 2 in stromal fibroblasts. PDF Medulloblastoma: Fuelling the debate p222 | doi:10.1038/nrc3494 In medulloblastoma, placental growth factor (PLGF) may signal through a non-tyrosine kinase receptor, neuropilin 1 (NRP1), to promote tumour cell survival without having a substantial effect on angiogenesis, thus providing a rationale for targeting this pathway in these tumours. PDF TRIAL WATCH Oncolytics in the clinic | Avoiding relapse p223 | doi:10.1038/nrc3501 PDF Non-coding RNAs: The cancer X factor p224 | doi:10.1038/nrc3489 Eda Yildirim, Jeannie Lee and colleagues present intriguing evidence that the long non-coding RNA X-inactive specific transcript (Xist) is required for maintaining X-chromosome inactivation, and that the loss of Xist after X inactivation can cause haematopoietic cancers in mice. PDF Leukaemia: Holding back p224 | doi:10.1038/nrc3493 A recent paper published in Blood indicates that the interaction between AML1-ETO and the transcriptional co-repressor NCOR1 is partly responsible for limiting the leukaemogenic capacity of this fusion gene. PDF Tumour heterogeneity: The rise of the minority p225 | doi:10.1038/nrc3499 Landau, Carter, Stojanov and colleagues characterize genetic clonal evolution in chronic lymphocytic leukaemia and connect the occurrence of clonal evolution to therapy and prognosis. PDF IN BRIEF Breast cancer: Channelling oncogenicity | Signalling: A smooth alternative? | Immunotherapy: A vehicle for inflammation | Signalling: Chemokine underpinnings of a tumour PDF Cancer JOBS of the week Postdoctoral Fellow in Cancer Epigenetics University of Texas M. D. Anderson Cancer Head of Core Facilities Centre for Genomic Regulation (CRG) Mouse Liver Cancer Models National University of Singapore Marie Curie ITN – TIMCC funded PhD Student Barts Cancer Institute, Queen Mary University of London Assistant Researcher UCLA Department of Urology More Science jobs from Cancer EVENT Molecular Pathology and Diagnosis of Cancer 11.10.13 Cambridge, UK More science events from
PROGRESS		Top
Cancer metabolism: fatty acid oxidation in the limelight Arkaitz Carracedo, Lewis C. Cantley & Pier Paolo Pandolfi p227 | doi:10.1038/nrc3483 The vast majority of the research into cancer metabolism has been limited to a handful of metabolic pathways, with other pathways being sidelined. This Progress article brings to light the potential contribution of fatty acid oxidation to cancer cell function. Abstract | Full Text | PDF
Advertisement
Patient-Derived Xenograft Resource from JAX® Mice & Services Our patient-derived xenograft resource represents a significant improvement over existing cancer models. Tumors engrafted into the NSG mice closely match patient tumors in histology, gene expression and genetic markers. Learn more today.
REVIEWS		Top
Mechanistic links between COPD and lung cancer A. McGarry Houghton p233 | doi:10.1038/nrc3477 The presence of chronic obstructive pulmonary disease (COPD) is linked to an increased risk of developing lung cancer, independently of cigarette smoking dosage. This Review discusses the nature of the link between the two diseases and considers specific mechanisms that operate in both COPD and lung cancer. Abstract | Full Text | PDF
The Hippo pathway and human cancer Kieran F. Harvey, Xiaomeng Zhang & David M. Thomas p246 | doi:10.1038/nrc3458 A wealth of recent studies has characterized roles for the Hippo pathway in diverse cancer-relevant processes. This Review discusses our latest understanding of Hippo pathway signalling in cancer, including mechanisms of pathway disruption in cancer, and the opportunities and challenges for therapeutic intervention. Abstract | Full Text | PDF | Supplementary information
The effects of PEDF on cancer biology: mechanisms of action and therapeutic potential S. Patricia Becerra & Vicente Notario p258 | doi:10.1038/nrc3484 Pigment epithelium-derived factor (PEDF) has anti-angiogenic, antitumorigenic and antimetastatic properties. If PEDF is to be used for cancer management, a deeper appreciation of its many functions and mechanisms of action is needed, as discussed in this Review. Abstract | Full Text | PDF
Advertisement
Accelerate your research with the Gel DocTM EZ System and Image Lab™ software. With the push of a button this award-winning solution gives you publication-ready imaging results in just 10 seconds.;
PERSPECTIVES		Top
OPINION Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research Emma Kipps, David S. P. Tan & Stan B. Kaye p273 | doi:10.1038/nrc3432 Malignant ascites presents a considerable clinical challenge to the management of ovarian cancer. This Opinion article discusses recent advances in our understanding of its pathophysiology, the development of new methods to characterize its molecular features and how these findings can be used to improve the treatment of malignant ascites. Abstract | Full Text | PDF
OPINION Translational control of cell growth and malignancy by the CPEBs Andrea D'Ambrogio, Kentaro Nagaoka & Joel D. Richter p283 | doi:10.1038/nrc3485 The CPEBs regulate polyadenylation — and thus expression — of certain RNAs, including those encoding oncogenes and tumour suppressors. This Opinion article analyses whether the CPEBs are deregulated in cancer and discusses the possible implications for cancer biology. Abstract | Full Text | PDF | Supplementary information
Advertisement
Ludwig Institute for Cancer Research, Nature Genetics, and Nature Reviews Cancer present: Nuclear Reprogramming and the Cancer Genome St. Catherine's College, University of Oxford, Oxford, UK September 25-27, 2013 Click here for more information or to register for this conference today!
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2011 Journal Citation Report (Thomson Reuters, 2012)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.